Skip to main content

Hyseq, UCSF License Heart Database to Celera Diagnostics

NEW YORK, Sept. 9-Celera Diagnostics has signed an agreement with Hyseq Pharmaceuticals and the University of California at San Francisco for access to a large collection of samples from cardiovascular patients, Hyseq announced today.

 

The database includes more than 12,000 DNA samples and related clinical information.

 

Celera will use the collection to study the genetics of cardiovascular disease.

 

The license is non-exclusive. Financial terms were not disclosed.

 

For more information, see the press release.

 

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.